PMID- 36094455
OWN - NLM
STAT- MEDLINE
DCOM- 20221007
LR  - 20230316
IS  - 1531-7080 (Electronic)
IS  - 0268-4705 (Linking)
VI  - 37
IP  - 6
DP  - 2022 Nov 1
TI  - Is the world ready for the STICH 3.0 trial?
PG  - 474-480
LID - 10.1097/HCO.0000000000001000 [doi]
AB  - PURPOSE OF REVIEW: Coronary artery disease (CAD) is responsible for >50% of heart 
      failures cases. Patients with ischemic left ventricular systolic dysfunction 
      (iLVSD) are known to have poorer outcomes after percutaneous coronary 
      intervention (PCI) and coronary artery bypass grafting (CABG) compared to 
      patients with a normal ejection fraction. Nevertheless, <1% of patients in 
      coronary revascularization trials to date had iLVSD. The purpose of this review 
      is to describe coronary revascularization modalities in patients with iLVSD and 
      highlight the need for randomized controlled trial evidence comparing these 
      treatments in this patient population. RECENT FINDINGS: Network meta-analytic 
      findings of observational studies suggest that PCI is associated with higher 
      rates of mortality, cardiac death, myocardial infarction, and repeat 
      revascularization but not stroke compared to CABG in iLVSD. In recent years, 
      outcomes for patients undergoing PCI have improved as a result of advances in 
      technologies and techniques. SUMMARY: The optimal coronary revascularization 
      modality in patients with iLVSD remains unknown. In observational studies, CABG 
      appears superior to PCI; however, direct randomized evidence is absent and 
      developments in PCI techniques have improved post-PCI outcomes in recent years. 
      The Surgical Treatment for Ischemic Heart Failure 3.0 consortium of trials will 
      seek to address the clinical equipoise in coronary revascularization in patients 
      with iLVSD.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Vervoort, Dominique
AU  - Vervoort D
AD  - Institute of Health Policy, Management and Evaluation.
AD  - Division of Cardiac Surgery, University of Toronto, Toronto, Ontario.
FAU - Jolicoeur, Marc E
AU  - Jolicoeur ME
AD  - Montreal Heart Institute, University of Montreal, Montreal, Quebec.
FAU - Marquis-Gravel, Guillaume
AU  - Marquis-Gravel G
AD  - Montreal Heart Institute, University of Montreal, Montreal, Quebec.
FAU - Fremes, Stephen E
AU  - Fremes SE
AD  - Institute of Health Policy, Management and Evaluation.
AD  - Division of Cardiac Surgery, University of Toronto, Toronto, Ontario.
AD  - Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, 
      Toronto, Ontario, Canada.
LA  - eng
GR  - 471008/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220912
PL  - United States
TA  - Curr Opin Cardiol
JT  - Current opinion in cardiology
JID - 8608087
SB  - IM
MH  - Coronary Artery Bypass/methods
MH  - *Coronary Artery Disease/therapy
MH  - Humans
MH  - *Myocardial Infarction/etiology
MH  - *Percutaneous Coronary Intervention/methods
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
MH  - *Ventricular Dysfunction, Left/surgery
EDAT- 2022/09/13 06:00
MHDA- 2022/10/12 06:00
CRDT- 2022/09/12 11:38
PHST- 2022/09/13 06:00 [pubmed]
PHST- 2022/10/12 06:00 [medline]
PHST- 2022/09/12 11:38 [entrez]
AID - 00001573-202211000-00007 [pii]
AID - 10.1097/HCO.0000000000001000 [doi]
PST - ppublish
SO  - Curr Opin Cardiol. 2022 Nov 1;37(6):474-480. doi: 10.1097/HCO.0000000000001000. 
      Epub 2022 Sep 12.